Eli Lilly Aktie

750,10 EUR +21,40 EUR +2,94 %

19:57:20

STU

780,05 USD +22,62 USD +2,99 %

19:59:50

BTT

Aktien, ETFs, Sparpläne & Kryptos zu Top-Konditionen beim Testsieger von finanztip.de handeln!

JETZT LOSLEGEN

Du hast schon ein ZERO-Konto? Direkt handeln bei ZERO!Bei einem anderen Broker handeln Smartphone

Marktkap.698,50 Mrd. EUR

KGV100,48Div. Rendite0,78%

WKN858560

ISINUS5324571083

SymbolLLY

Eli Lilly Aktien News

Sortieren:Datum Meistgelesen

06.05.24PR NewswireLilly Declares Second-Quarter 2024 Dividend

06.05.24EN, Eli LillyLilly Declares Second-Quarter 2024 Dividend

30.04.24EN, Eli LillyLilly Reports First-Quarter 2024 Financial Results and Raises Full-Year Revenue Guidance by $2 Billion, Highlights Pipeline Momentum

30.04.24PR NewswireLilly Reports First-Quarter 2024 Financial Results and Raises Full-Year Revenue Guidance by $2 Billion, Highlights Pipeline Momentum

26.04.24EN, Eli LillyLilly Recommends Shareholders Reject “Mini-Tender” Offer by Tutanota LLC

22.04.24EN, Eli LillyLilly Acquires New Injectable Medicine Manufacturing Facility from Nexus Pharmaceuticals

17.04.24PR NewswireTirzepatide reduced sleep apnea severity by up to nearly two-thirds in adults with obstructive sleep apnea (OSA) and obesity

17.04.24EN, Eli LillyTirzepatide reduced sleep apnea severity by up to nearly two-thirds in adults with obstructive sleep apnea (OSA) and obesity

16.04.24PR NewswireLilly Confirms Date and Conference Call for First-Quarter 2024 Financial Results Announcement

16.04.24EN, Eli LillyLilly Confirms Date and Conference Call for First-Quarter 2024 Financial Results Announcement

06.04.24EN, Eli LillyResults announced from EMPACT-MI phase III trial investigating the effect of Jardiance® (empagliflozin) on risk of heart failure hospitalization and death in adults following a heart attack

10.03.24PR NewswireMore than two-thirds of people with atopic dermatitis and skin of color experienced skin improvement in a first-of-its-kind lebrikizumab study

10.03.24EN, Eli LillyMore than two-thirds of people with atopic dermatitis and skin of color experienced skin improvement in a first-of-its-kind lebrikizumab study

08.03.24PR NewswireU.S. Food and Drug Administration to Convene Advisory Committee Meeting to Discuss the TRAILBLAZER-ALZ 2 Study of Donanemab

08.03.24EN, Eli LillyU.S. Food and Drug Administration to Convene Advisory Committee Meeting to Discuss the TRAILBLAZER-ALZ 2 Study of Donanemab

07.03.24EN, Eli LillyOpen Letter Regarding the Use of Mounjaro® (tirzepatide) and Zepbound® (tirzepatide)

07.03.24PR NewswireLilly's Newest Phase of Get Better Campaign Challenges Misperceptions About Obesity Care

07.03.24EN, Eli LillyLilly's Newest Phase of Get Better Campaign Challenges Misperceptions About Obesity Care

05.03.24PR NewswireLilly Announces Details of Presentations at 2024 American Association for Cancer Research (AACR) Annual Meeting

05.03.24EN, Eli LillyLilly Announces Details of Presentations at 2024 American Association for Cancer Research (AACR) Annual Meeting

20.02.24EN, Eli LillyLilly to Participate in Cowen's 44th Annual Health Care Conference

20.02.24PR NewswireLilly to Participate in Cowen's 44th Annual Health Care Conference

09.02.24EN, Eli LillyPhilip Johnson to Retire as Lilly Treasurer

09.02.24PR NewswirePhilip Johnson to Retire as Lilly Treasurer

06.02.24PR NewswireLilly Reports Strong Fourth-Quarter 2023 Financial Results and Provides 2024 Guidance

06.02.24EN, Eli LillyLilly Reports Strong Fourth-Quarter 2023 Financial Results and Provides 2024 Guidance

25.01.24PR NewswireJohna Norton to Retire as Lilly Executive Vice President of Global Quality

25.01.24EN, Eli LillyJohna Norton to Retire as Lilly Executive Vice President of Global Quality

23.01.24EN, Eli LillyPositive Phase 1/2 Clinical Trial Data for an Investigational Gene Therapy for Genetic Hearing Loss to be Presented at the Association for Research in Otolaryngology 2024 MidWinter Meeting

23.01.24PR NewswirePositive Phase 1/2 Clinical Trial Data for an Investigational Gene Therapy for Genetic Hearing Loss to be Presented at the Association for Research in Otolaryngology 2024 MidWinter Meeting

23.01.24EN, Eli LillyLilly Confirms Date and Conference Call for Fourth-Quarter 2023 Financial Results and 2024 Financial Guidance

23.01.24PR NewswireLilly Confirms Date and Conference Call for Fourth-Quarter 2023 Financial Results and 2024 Financial Guidance

04.01.24EN, Eli LillyLilly Launches End-to-End Digital Healthcare Experience through LillyDirect™

04.01.24PR NewswireLilly Launches End-to-End Digital Healthcare Experience through LillyDirect™

04.01.24EN, Eli Lilly Open Letter Regarding the Use of Mounjaro® (tirzepatide) and Zepbound™ (tirzepatide)

02.01.24EN, Eli LillyLilly to Participate in J.P. Morgan Healthcare Conference

02.01.24PR NewswireLilly to Participate in J.P. Morgan Healthcare Conference

27.12.23EN, Eli LillyLilly Completes Acquisition of POINT Biopharma

27.12.23PR NewswireLilly Completes Acquisition of POINT Biopharma

18.12.23PR NewswireLilly Extends Tender Offer to Acquire POINT Biopharma to Dec. 22, 2023

Eli Lilly News

Eli Lilly News: auf dieser Seite finden Sie alle Eli Lilly News und Nachrichten zur Eli Lilly Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Eli Lilly News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Eli Lilly News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.